OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Investigator: Jeffrey Rothstein

3 Projects | 1 Researchers | $545,991 Invested

2024

Johns Hopkins University

Jeffrey Rothstein, MD, PhD

Mitigating TDP-43 loss of function and disease initiation in FTD thru repair of the Nuclear Pore and CHMP7/ESCRT3 dysfunction.

  • Funding Amount: $269,967
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: TDP-43
  • Status: Active

2013

Johns Hopkins University

Jeffrey Rothstein, MD, PhD

Biomarker assay development to accompany antisense oligonucleotide therapeutic for mutant C9orf72-positive FTD patients

  • Funding Amount: $150,168
  • Organization Type: Academic/Nonprofit
  • Program: Biomarkers
  • Target: Other
  • Status: Closed

2012

Johns Hopkins University

Jeffrey Rothstein, MD, PhD

Development of Antisense therapy and Therapeutic biomarker for C9orf72 FTD/ALS mutation patients

  • Funding Amount: $125,856
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Other
  • Status: Closed